Dosing reference
Every dose that has been studied in humans
Label dosing for approved drugs, the amounts given in registered trials of investigational drugs, and a plain “none established” everywhere else. No forum numbers, no vendor charts. Every figure cites its source.
22 · FDA label15 · Trial doses71 · None established
Reconstitution guide
Lab steps with photos, syringe units and storage.
How long studies ran
Cycle-length evidence: treatment and follow-up durations.
Combinations
What is actually studied when compounds are paired.
Human dosing quick-reference chart
Click any compound for the cited dosing page, study durations and vial arithmetic.
| Compound | Research area | Status | Human amounts | Route studied | Half-life | Evidence | |
|---|---|---|---|---|---|---|---|
| Abaloparatide | Hormonal | FDA-approved | 80 micrograms once daily | Subcutaneous injection | Approximately 1 hour | A | View |
| Apelin-13 | Hormonal | Not approved | None established | — | Not located as a numeric value in the sources reviewed. Rapid plasma clearance is described as a limitation that motivates delivery work such as microneedle patches . | B | View |
| Gonadorelin | Hormonal | Approved, no longer marketed | Label not retrievable | — | A review describes native GnRH as having low potency and a short half-life, which is why longer-acting analogues were developed; it gives no numerical value, and no half-life figure for gonadorelin was verified for this entry . | B | View |
| hCG (human chorionic gonadotropin) | Hormonal | FDA-approved | Label regimens vary by indication, e.g. 5,000 to 10,000 USP units once, one day after the last gonadotropin dose, for ovulation induction (Novarel/Pregnyl) | Intramuscular (Novarel, Pregnyl) | About 29 hours (recombinant hCG, subcutaneous; Ovidrel label) | A | View |
| Kisspeptin-10 | Hormonal | Not approved | None established | — | — | B | View |
| Kisspeptin-54 | Hormonal | Not approved | None established | Studied intravenously, subcutaneously and intranasally in research settings | About 28 minutes (intravenous, healthy men) | B | View |
| Leuprolide | Hormonal | FDA-approved | Prostate cancer (Lupron Depot): 7.5 mg every 4 weeks, 22.5 mg every 12 weeks, 30 mg every 16 weeks or 45 mg every 24 weeks. Endometriosis/fibroids (Lupron Depot 3.75 mg): 3.75 mg monthly. CPP: weight-based (Lupron Depot-PED) | Intramuscular depot (Lupron Depot); subcutaneous (Eligard) | Approximately 3 hours (elimination, two-compartment model) | A | View |
| Octreotide | Hormonal | FDA-approved | Acromegaly: Sandostatin 50 mcg three times daily initially (maintenance 100-500 mcg three times daily); Sandostatin LAR 20 mg every 4 weeks for 3 months initially; Mycapssa 20 mg twice daily initially (maximum 80 mg daily) | Subcutaneous or intravenous (injection); intragluteal intramuscular (LAR); oral (Mycapssa) | 1.7-1.9 hours (injection) | A | View |
| PE-22-28 | Hormonal | Not approved | None established | — | — | C | View |
| PT-141 | Hormonal | FDA-approved | 1.75 mg subcutaneously as needed, at least 45 minutes before anticipated sexual activity; no more than one dose in 24 hours or 8 per month (FDA label) | Subcutaneous (single-dose autoinjector) | Mean terminal half-life of about 2.7 hours (range 1.9 to 4.0 hours) after a single subcutaneous administration, per the FDA label . | A | View |
| Teduglutide | Hormonal | FDA-approved | 0.05 mg/kg once daily (adults and children 1 year and older); 0.025 mg/kg once daily if eGFR is below 60 mL/min/1.73 m2 (GATTEX label) | Subcutaneous injection | About 2 hours (healthy) and 1.3 hours (SBS) | A | View |
| Teriparatide | Hormonal | FDA-approved | 20 micrograms once daily | Subcutaneous injection | Approximately 1 hour | A | View |
| TRH (Thyrotropin) | Hormonal | Approved, no longer marketed | Label not retrievable | — | A patent and development review states that TRH has a short plasma half-life of about five minutes, which it gives as one reason the native hormone is a poor drug candidate . | A | View |
| Triptorelin | Hormonal | FDA-approved | Prostate cancer (Trelstar): 3.75 mg every 4 weeks, 11.25 mg every 12 weeks or 22.5 mg every 24 weeks. CPP (Triptodur): 22.5 mg every 24 weeks | Intramuscular injection | Terminal half-life about 3 hours after IV bolus (3-compartment model, healthy men) | A | View |
| Vasopressin | Hormonal | FDA-approved | Septic shock: start 0.01 units/minute (range 0.01-0.07); post-cardiotomy shock: start 0.03 units/minute (range 0.03-0.1); titrate by 0.005 units/minute every 10-15 minutes (Vasostrict label) | Intravenous infusion | 10 minutes or less at shock infusion rates | A | View |
“Human amounts” is a summary; the dosing page for each compound carries the full cited statements. Compounds approved nowhere show “None established” by policy, whatever is circulated elsewhere. Why.
What every dosing page includes
- Quick-reference card
- Label or trial doses, cited
- How long studies ran
- Who was excluded
- Side effects reported
- Reconstitution arithmetic + syringe chart
- Supplies, storage and handling mistakes
- Regulatory status
- Comparison with related compounds
- Combinations and FAQs
Don’t see a compound?
Tell us what to research next. We add compounds when there are primary sources to cite.